Solensia

Frunevetmab anti-NGF monoclonal antibody for osteoarthritis pain in cats; monthly subcutaneous injection. Anti-NGF monoclonal antibody (frunevetmab). Mechanism: felinized anti-nerve growth factor (NGF) IgG4 monoclonal antibody → specifically neutralizes feline NGF → prevents NGF binding to TrkA and p75NTR receptors → reduced sensitization of pain pathways → osteoarthritis pain relief in cats. Monthly SQ injection. Sustained pharmacokinetics. Key information Frunevetmab — anti-NGF monoclonal antibody for feline OA pain. Refrigerate; do not freeze. Subcutaneous injection monthly. Cats only.

SQ injection: administer SQ in the dorsal neck or scruff region. Monthly administration. Use correct dose per body weight. Store refrigerated (2–8°C); do not freeze. Bring to room temperature before injection. Single-use vial. If a dose is missed This product is given as a single dose or as part of a defined protocol. Contact your veterinarian if a scheduled administration was missed. Solensia is given monthly — contact your veterinarian to reschedule.

Injection site reactions (most common — transient pain, swelling). GI: vomiting (uncommon). Neurological: paresis, ataxia (rare — post-marketing). Renal: azotemia (rare). Generally very well tolerated in cats.

For animals Cats only — do not use canine anti-NGF antibody (librela/bedinvetmab) in cats. Post-marketing: neurological signs (paresis, ataxia) reported rarely — monitor closely. Monitor renal function, hydration status, and urine output. Not for breeding, pregnant, or lactating cats. Not approved for use in food-producing animals. For people handling this medication Administered by veterinary professionals only. No specific human precautions for caregivers beyond normal hygiene.

Contact your veterinarian. Monoclonal antibody overdose — unlikely to cause serious toxicity. Contact vet for guidance.